Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptor‐mutant non‐small cell lung cancer: A prospective, multicenter, dose‐modification study

AIM: Gefitinib and erlotinib are efficacious and safe for older patients with epidermal growth factor receptor‐mutant non‐small cell lung cancer. However, prolonged use of epidermal growth factor receptor‐tyrosine kinase inhibitors in older patients is difficult, owing to potential adverse events. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsubata, Yukari, Masuda, Takeshi, Hamai, Kosuke, Taniwaki, Masaya, Tanino, Akari, Hotta, Takamasa, Hamaguchi, Megumi, Hamaguchi, Shunichi, Yamasaki, Masahiro, Ishikawa, Nobuhisa, Fujitaka, Kazunori, Sutani, Akihisa, Isobe, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles: Epidemiology, Clinical Practice and Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518893/
https://www.ncbi.nlm.nih.gov/pubmed/34378299
http://dx.doi.org/10.1111/ggi.14243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518893/
https://www.ncbi.nlm.nih.gov/pubmed/34378299
http://dx.doi.org/10.1111/ggi.14243

Ejemplares similares